has function has role immunizes against disease immunizes recipient breast cancer ovarian cancer Homo sapiens therapeutic vaccine function vaccine in clinical trial role breast cancer vaccine ovarian cancer vaccine liposomal MUC1/PET-lipid A vaccine Justin Song VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5488 cancer vaccine 5488 https://github.com/vaccineontology/VO/issues/479 Gene name: MUC1 4582 Yuanyi (Penny) Pan A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen. Jie Zheng Oliver He therapeutic cancer vaccine